jueves, 12 de diciembre de 2013

NIAID Researchers Identify Potential Anti-Clotting Drug

NIAID Researchers Identify Potential Anti-Clotting Drug

Leading Research to Understand, Treat, and Prevent Infectious, Immunologic, and Allergic Diseases
NIAID News Twitter   NIAID Facebook   NIAID News Twitter   LinkedIn Icon
Visit us on the Web
NIAID Researchers Identify Potential Anti-Clotting Drug
NIAID investigators have identified in vampire bat saliva a novel anticoagulant called Desmolaris. The protein prevented clot formation in the arteries of mice at doses that did not promote bleeding. The findings are published in the December 12 issue of Blood.
The study suggests that Desmolaris could be used as an anti-clotting drug or as a prototype for development of new therapies to prevent and treat conditions such as arterial thrombosis and stroke. Desmolaris-based therapies may be safer than current anticoagulant drugs, which carry a high risk of bleeding.
Read more about the study.

No hay comentarios:

Publicar un comentario